NEWPORT BEACH, Calif. - Evolus, Inc. (NASDAQ: NASDAQ:EOLS), a performance beauty company, has announced the publication of a study in the Aesthetic Surgery Journal that supports the safety and efficacy of its product, Jeuveau® (prabotulinumtoxinA-xvfs), for the treatment of moderate to severe glabellar lines, commonly known as frown lines, in adults.
The Phase 2 study results indicate that the product's effects last for a duration of 26 weeks, or 6 months.
The multicenter, double-blind, randomized Phase 2 trial involved 150 patients and compared the 40-unit dosage of Jeuveau® against two active controls: 20 units of BOTOX® and 20 units of Jeuveau®. The study aimed to evaluate the duration of effect, safety, and efficacy of the product.
According to the results, the duration of effect for patients who showed at least a one-point improvement on the Glabellar Line Scale (GLS) was 26 weeks. Additionally, the majority of adverse events were classified as mild, and no serious adverse events were reported.
Dr. Rui Avelar, Chief Medical Officer and Head of R&D at Evolus, stated that the study confirms the correlation between increased dosage and increased duration while maintaining a similar safety profile.
Jeuveau® is approved in the United States under the brand name Jeuveau® and in Europe and Canada as Nuceiva®. The product received regulatory approval in Australia in January 2023. It is designed for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in individuals younger than 65 years.
Evolus is evolving the aesthetic neurotoxin market and aims to become a global multi-product aesthetics company. The company is also set to be the exclusive U.S. distributor of Evolysse™, a line of dermal fillers currently in late-stage development.
The information in this article is based on a press release statement from Evolus, Inc.
InvestingPro Insights
As Evolus, Inc. (NASDAQ: EOLS) continues to make strides in the aesthetics market with its flagship product, Jeuveau®, the company's financial health and market performance provide a broader context for investors.
According to real-time data from InvestingPro, Evolus currently holds a market capitalization of $715.83 million. Despite not being profitable over the last twelve months, as indicated by a negative P/E ratio of -10.77, the company has seen a substantial revenue growth of 35.98% during the same period. This suggests an expanding market presence and increased sales of its products.
InvestingPro Tips highlight that Evolus operates with a moderate level of debt and possesses liquid assets that exceed short-term obligations, which could provide financial flexibility in its operations and investments.
Moreover, the stock has experienced a large price uptick over the last six months, with a 42.1% price total return, reflecting investor optimism about the company's growth prospects. Notably, analysts do not anticipate the company will be profitable this year, and Evolus does not pay a dividend to shareholders, which might be a consideration for income-focused investors.
For those interested in a deeper analysis of Evolus, Inc., there are additional InvestingPro Tips available that could further inform investment decisions. To explore these insights, visit InvestingPro and consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.